Symyx Inc. began life as a distinctly non-biotech company, using combinatorial techniques in the material sciences, even though these methods were originally applied to drug discovery. But the company's expertise in polymers has led it full circle to applications in the life sciences. SMMX, which recently completed a $77.5 million IPO